Related Experiment Video
Updated: Mar 18, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
An Overview on Predictive Biomarkers of Testicular Germ Cell Tumors
1Dipartimento di Psicologia, Seconda Università di Napoli, Caserta, Italy. Paolo.Chieffi@unina2.it.
Abstract:
Testicular germ cell tumors (TGCTs) are frequent solid malignant tumors and cause of death in men between 20-40 years of age. Genetic and environmental factors play an important role in the origin and development of TGCTs. Although the majority of TGCTs are responsive to chemotherapy, about 20% of patient presents incomplete response or tumors relapse. In addition, the current treatments cause acute toxicity and several chronic collateral effects, including sterility. The present mini-review collectively summarize the most recent findings on the new discovered molecular biomarkers such as tyrosine kinases, HMGAs, Aurora B kinase, and GPR30 receptor predictive of TGCTs and as emerging new possible molecular targets for therapeutic strategies. J. Cell. Physiol. 232: 276-280, 2017. © 2016 Wiley Periodicals, Inc.
Insights
Testicular germ cell tumors (TGCTs) are a common cancer in young men. This review highlights new molecular biomarkers and therapeutic targets for improved TGCT treatment and outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Testicular germ cell tumors (TGCTs) are the most common solid malignant tumors in men aged 20-40.
- While chemotherapy is effective for most TGCTs, approximately 20% of patients experience incomplete response or relapse.
- Current treatments for TGCTs can lead to significant acute toxicity and chronic side effects, including sterility.
Purpose of the Study:
- To review recent findings on novel molecular biomarkers for TGCTs.
- To identify emerging molecular targets for potential therapeutic strategies in TGCT treatment.
Main Methods:
- Literature review of recent scientific findings.
- Analysis of molecular biomarkers associated with TGCT origin, development, and treatment response.
Main Results:
- Identification of tyrosine kinases, High Mobility Group AT-hook proteins (HMGAs), Aurora B kinase, and G protein-coupled receptor 30 (GPR30) as significant molecular biomarkers.
- These biomarkers show predictive value for TGCTs and represent potential therapeutic targets.
Conclusions:
- Novel molecular biomarkers offer promising avenues for improving TGCT diagnosis and treatment.
- Targeting these biomarkers may lead to more effective and less toxic therapeutic strategies for TGCT patients.
